Caris Life Sciences, Inc.

Caris Life Sciences reported a significant improvement in its financial performance for the second quarter and first half of 2026. Total revenue for Q2 2026 increased by 45.4% to $263.7 million, with net loss narrowing substantially to $(0.6) million from $(71.8) million in the prior year. For the first six months of 2026, total revenue grew 58.7% to $479.9 million, and the company generated $61.4 million in net cash from operating activities, a turnaround from cash used in the previous year.

Caris Life Sciences reported strong financial results for the second quarter of 2026, with total revenue increasing 45% year-over-year to $263.7 million and a significant reduction in net loss to $0.6 million. The company achieved positive Adjusted EBITDA of $55.7 million and positive free cash flow of $6.4 million. Following this performance, Caris Life Sciences raised its full-year 2026 revenue guidance to a range of $1.03 billion to $1.04 billion, reflecting continued growth and operational improvements. Additionally, the company launched several new products, including Caris Detect, and announced a share repurchase program.

Caris Life Sciences reported a significant improvement in its financial performance for Q1 2026. Total revenue surged by 78.8% to $216.2 million, primarily driven by an 84.8% increase in molecular profiling services. The company dramatically reduced its net loss from $102.6 million in Q1 2025 to just $0.5 million in Q1 2026, with net loss per share improving to $0.00. Operating cash flow also turned positive, reaching $32.9 million.

Caris Life Sciences reported strong first-quarter 2026 financial results, with total revenue increasing 79% to $216.2 million and a significant reduction in net loss to $0.5 million. The company achieved positive Adjusted EBITDA of $26.2 million and positive free cash flow of $22.5 million. Operational highlights included the launch of new diagnostic tools like Caris ChromoSeq and Caris MI Clarity, and the reaffirmation of its full-year 2026 revenue guidance of $1.0 billion to $1.02 billion. Clinical therapy selection cases also rose 15% to approximately 52,800.